MarketPulse

solid tumors

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ipsen Unveils Early-Stage Immuno-Oncology Breakthroughs at AACR Congress

Ipsen presents preclinical data for two first-in-class cancer candidates targeting solid tumors and gastrointestinal cancers, advancing its immuno-oncology pipeline.
IPSEYantibody-drug conjugatesolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Launches Global Trial for Dual-Action Tumor Therapy HMPL-A580

HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a novel antibody-targeted therapy combining PI3K/PIKK inhibitor with anti-EGFR antibody for solid tumors across China and US.
HCMclinical developmentsolid tumors
BenzingaBenzinga··Globe Newswire

Bicara Therapeutics Raises $172.5M in Oversubscribed Offering

Bicara Therapeutics raises $172.5M in oversubscribed offering, with proceeds funding development of lead immunotherapy candidate ficerafusp alfa for solid tumors.
BCAXclinical-stageEGFR
BenzingaBenzinga··Globe Newswire

Bicara Therapeutics Plans $150M Stock Offering to Fund Pipeline Advancement

Bicara Therapeutics plans $150M stock offering to advance its lead drug candidate ficerafusp alfa through clinical development and build commercial infrastructure for potential market launch.
BCAXclinical-stageEGFR
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Calidi Biotherapeutics Advances Tumor-Targeted BiTE Platform Toward Clinical Development

Calidi Biotherapeutics advances RedTail virotherapy platform combining BiTE and IL-15 therapies for solid tumors, aiming to overcome immunosuppressive microenvironments. IND submission planned for 2026.
CLDIsolid tumorsRedTail platform